For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 153,351 | |||
| General and administrative | 24,183 | |||
| Total operating expenses | 177,534 | |||
| Operating loss | -177,534 | |||
| Interest and investment income | 11,226 | |||
| Net loss | -166,308 | |||
| Unrealized gain (loss) on marketable securities | 225 | |||
| Total other comprehensive gain (loss) | 225 | |||
| Total comprehensive loss | -166,083 | |||
| Basic EPS | -4.32 | |||
| Diluted EPS | -4.32 | |||
| Basic Average Shares | 38,462,600 | |||
| Diluted Average Shares | 38,462,600 | |||
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)